Paricalcitol (19-nor-1,25-hydroxi-vitamin D2), a selective, new generation vitamin D receptor activator, has been proven to be beneficial in the control of secondary hyperparathyroidism both in hemodialysis and predialysis patients with less calcemic and phosphatemic effects [16, 17]. The gene discussed is VDR; the disease is secondary hyperparathyroidism.